True Wealth Design’s Lifecore Biomedical LFCR Stock Holding History

True Wealth Design’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12	Closed	-$45	–	2782
2026 Q1	$45	Hold	12	–	–	﹤0.01%	2573
2025 Q4	$99	Hold	12	–	–	﹤0.01%	2345
2025 Q3	$89	Hold	12	–	–	﹤0.01%	2471
2025 Q2	$98	Buy	12 +6	+100%	+$40	﹤0.01%	2243
2025 Q1	$43	Buy	+6	New	+$37	﹤0.01%	2421

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

True Wealth Design's LFCR Position: Q2 2026 in Review

True Wealth Design sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 12 shares — an estimated $45 sold.

True Wealth Design first reported a position in LFCR in Q1 2025 and held it in 5 quarters. The position peaked at $99 in Q4 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

True Wealth Design reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
True Wealth Design sold 12 Lifecore Biomedical shares in Q2 2026, an estimated $45.
True Wealth Design first reported a position in Lifecore Biomedical in Q1 2025 and held it in 5 quarters.
True Wealth Design's Lifecore Biomedical position peaked at $99 in Q4 2025.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.